All In Biotech

BLA 125513 · Alexion Pharm

Strensiq

Asfotase Alfa · Injection · Tissue-nonspecific Alkaline Phosphatase

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Oct 23, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

16

4 Phase 3, 1 recruiting

FAERS reports

10,322

3,394 serious, 79 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate STRENSIQ under the supervision of a healthcare provider with appropriate medical monitoring and support measures. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue STRENSIQ and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS See full prescribing information...

What it is approved for

From the label in effect Dec 12, 2025.

STRENSIQ ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). STRENSIQ is a tissue nonspecific alkaline phosphatase indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). ( 1 )

Mechanism: HPP is caused by a deficiency in TNSALP enzyme activity, which leads to elevations in several TNSALP substrates, including inorganic pyrophosphate (PPi). TNSALP is a metallo-enzyme that catalyzes the hydrolysis of phosphomonoesters with release of inorganic phosphate and alcohol. Elevated extracellular levels of PPi block hydroxyapatite crystal growth which inhibits bone mineralization and causes an accumulation of unmineralized bone matrix which manifests as rickets and bone deformation in infants and children and as osteomalacia (softening of bones) once growth plates close, along with...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 12, 2020 Supplement 18 · Efficacy OrphanLabelLetter
  • Oct 23, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelSummary ReviewReview
4 products under this application
  • STRENSIQ · ASFOTASE ALFA 80MG/0.8ML · SOLUTION, INJECTION · Prescription
  • STRENSIQ · ASFOTASE ALFA 28MG/0.7ML · SOLUTION, INJECTION · Prescription
  • STRENSIQ · ASFOTASE ALFA 40MG/ML · SOLUTION, INJECTION · Prescription
  • STRENSIQ · ASFOTASE ALFA 18MG/0.45ML · SOLUTION, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Asfotase Alfa" as an intervention, any sponsor and status, largest first.

All 16 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • injection site pain1,351
  • fatigue1,029
  • injection site erythema881
  • pain851
  • injection site reaction778
  • arthralgia713
  • pain in extremity564
  • injection site bruising513
  • injection site swelling442
  • headache416
  • injection site pruritus344
  • bone pain323

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201533
2016785
20171,088
20181,301
20191,057
2020259
2021206
2022172
2023714
20242,432
20251,084
20261,191

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Strensiq (Asfotase Alfa)

2024 spending

$346M

Beneficiaries

290

3,431 claims

Per beneficiary

$1,193,004

$6,147.95 per unit

View as table
YearSpending
2020$139,626,523
2021$179,636,998
2022$220,781,958
2023$258,940,106
2024$345,971,144

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.